Nuvo Resources

A team from Sheba Medical Center is presenting a poster titled "Empowering High-Risk Pregnant Women: A New Hybrid Model for Hospital at Home" at the World Hospital at Home Congress, taking place March 27–29, 2025, at the Austria Center Vienna (ACV), Bruno-Kreisky-Platz 1, 1220 Wien, Austria. The work introduces a hybrid maternal-fetal care model integrating remote monitoring with in-clinic assessments for high-risk pregnancies.

The study highlights the use of INVU™ by Nuvo to support remote non-stress testing and enhance care for women with high-risk pregnancies, improving patient adherence and reducing visit time.

Authored by Nirit Putievsky Pilosof, Rakefet Yoeli-Ullman, Esther Galler, Galia Barkai, Eyal Zimlichman, and Abraham Tsur, the poster demonstrates Sheba's ongoing work in maternal care innovation and Nuvo's role in enabling remote pregnancy monitoring.

‍

‍

‍

Nuvo is pleased to announce its partnership with MFM Associates, a leading maternal-fetal medicine practice in New York City, to bring INVU by Nuvo to expectant mothers across the region. This collaboration enables patients at MFM Associates’ New York City offices to access FDA-cleared remote Non-Stress Tests (NSTs), enhancing pregnancy monitoring with advanced, physician-prescribed technology. The partnership is particularly valuable for high-risk pregnancies during the third trimester, improving access to essential maternal-fetal care for patients in the tri-state area, including Connecticut (CT), New York (NY), and New Jersey (NJ).

Expanding Access to Remote Pregnancy Monitoring in the Tri-State Area

INVU by Nuvo is a clinically validated, wearable maternal-fetal monitoring platform that allows for remote, non-invasive tracking of fetal heart rate, maternal heart rate, and uterine activity. This technology is particularly critical for high-risk pregnancies in the third trimester, where frequent monitoring is necessary to monitor fetal health.

This partnership with MFM Associates marks a significant step toward expanding access to modern, patient-centric pregnancy care, reducing the need for frequent in-office visits while ensuring continuous medical oversight for both mother and baby.

Benefits of INVU by Nuvo at MFM Associates

✔ Convenient, remote Non-Stress Tests (NSTs) from home

✔ Critical monitoring for high-risk pregnancies during the third trimester

✔ Real-time data transmission for physician review

✔ Optimized care for conditions like gestational diabetes, hypertension, and IUGR

✔ Seamless integration into MFM Associates’ clinical workflow

Now Available at MFM Associates in New York City

📍 East Side Office – 70 East 90th Street, New York, NY 10128

This partnership reflects Nuvo’s ongoing commitment to advancing maternal-fetal medicine through innovation, technology, and strategic collaborations with leading healthcare providers.

Learn more at https://www.mfmnyc.com/pregnancy-care/invu-by-nuvo/

‍

RAMAT GAN, Israel – February 24, 2025 – ARC, the global health innovation engine and transformation arm of world-leading hospital Sheba Medical Center,  announced today a collaboration with Nuvo Intl. Group Inc. (Nuvo), a pioneer in remote pregnancy monitoring.Under the partnership, ARC and Nuvo will develop advanced AI-driven solutions that enhance clinical decision-making, improve early detection of pregnancy complications, and redefine the quality of continuous pregnancy monitoring, leading to improved maternal and fetal outcomes.

The collaboration will createAI-based modules that equip clinicians with advanced decision-support tools, enhance diagnostic capabilities, and enable early intervention. Additionally, population health analysis will be conducted to improve the quality of prenatal care in the community.

Nuvo’s remote monitoring solution enables expectant mothers to track their pregnancy conveniently from home, the workplace, or anywhere else, significantly improving the prenatal care experience and pregnancy outcomes. Under the direction of Dr. Avi Tsur, OB/GYN and high-risk pregnancy expert and Director of the Women’s HealthInnovation Center at Sheba Beyond, Sheba Medical Center’s virtual hospital, the collaboration will integrate medical research with Nuvo’s cutting-edge technology.

This agreement is part ofSheba's commitment to becoming one of the world’s first fully-integrated AI hospitals. Through ARC, Sheba is transforming healthcare by using AI to enhance patient care, diagnostics, and treatment personalization. As a leader in AI health tech, Sheba collaborates with top institutions like the Mayo Clinic to integrate advanced AI solutions across its departments, positioning itself at the forefront of medical innovation.

Prof. Eyal Zimlichman, Chief Transformation and Innovation Officer and Director of ARC at Sheba Medical Center, said: “Our partnership with Nuvo represents the future of pregnancy care. Integrating AI-powered solutions into routine prenatal monitoring not only enhances pregnancy outcomes but also demonstrates how technology can revolutionize healthcare worldwide.”

Laurence Klein, CEO of Nuvo Intl Group Inc., said: “We are excited to embark on this collaborative commercial and research partnership with Sheba’s ARC program, predicated on innovative, AI-driven modules powered by the INVU platform. Sheba ARC and ShebaBeyond’s global leadership in advancing remote and hybrid pregnancy care is invaluable, and we look forward to driving meaningful transformation together.”

About ARC

ARC, founded in 2019, is driving the redesign of global healthcare through a structured approach to innovation to equip all parts of the health ecosystem with the tools and resources to advance healthcare delivery and improve outcomes. Through ARC’s continuous pipeline of innovation, ability to facilitate large-scale transformation, access to leading health organizations, and ability to drive economic growth and development, ARC equips all player types in the ecosystem to transform global health. For more information, visit: https://arcinnovation.org

About Sheba Medical Center

The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer, is generating global impact through its medical care, research, and healthcare transformation. Sheba’s City of Health boasts acute-care, rehabilitation, children’s, cancer, and geriatric hospitals, research and innovation hubs, a medical simulation center, and a center for disaster response on one comprehensive campus in the center of Israel. Sheba serves as a true hospital without borders, welcoming users and healthcare professionals from all over the world and consistently providing the highest-level medical care to all in need. Sheba has been ranked a World’s Best Hospital by Newsweek six years in a row (2019–2024). For more information, visit: https://sheba-global.com/

About Nuvo Intl. Group

Nuvo is leading a transformation in pregnancy care by providing clinicians and expectant mothers with access to medically-necessary remote pregnancy monitoring anytime, anywhere. Nuvo’s INVU™ platform is an FDA-and CE-cleared remote pregnancy monitoring and management system. It enables the delivery of remote non-stress tests (NSTs) and maternal and fetal heart rate monitoring while pioneering new data-driven personalized pathways that Nuvo believes can improve future health outcomes. INVU is being used by leading health providers and research institutions across the US and Israel. Nuvo plans to continue to expand the footprint of sales in the US and Israel to provide remote access and insights not previously deemed possible, while preparing for its market entry into Europe. Nuvo is led by a diverse team of experienced business, medical, and technology leaders, united in the mission of breaking down barriers to pregnancy care to give every life abetter beginning. For more information and complete indications, contraindications, warnings and precautions, and instructions for use, visit www.nuvocares.com

‍

The information contained in this press release is for informational purposes only and is not intended to serve as financial, legal, or investment advice. The content provided herein is based on current data as of the date of publication and is subject to change without notice.  This information may contain forward-looking statements, which include but are not limited to projections, plans, objectives, and future performance or assumptions underlying such statements. These statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein. Nuvo Intl. Group Inc. does not guarantee the accuracy, completeness, or timeliness of the information provided and expressly disclaims any liability for errors or omissions. Certain information has been provided by third-party sources and, although believed to be reliable, it has not been independently verified and its accuracy or completeness cannot be guaranteed.  Past performance is not indicative of future results. This information does not constitute an offer to sell or a solicitation to buy any securities or other financial instruments.

‍

Nuvo was honored to participate in the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, held from January 27 to February 1, 2025, at the Gaylord Rockies Resort in Denver, Colorado. The conference remains a pivotal event in maternal-fetal medicine, bringing together experts in high-risk pregnancies to discuss cutting-edge advancements in maternal and fetal care.

Throughout the week, Nuvo enjoyed reconnecting with long-time colleagues and forging new relationships with MFMs, partners, and researchers. A prominent theme at SMFM 2025 was the continued growth of remote pregnancy monitoring, an area in which Nuvo is pioneering innovative solutions.

Remote Pregnancy Monitoring at SMFM 2025

Dr. Nadav Schwartz held a dynamic poster presentation on "Empowering Patients to Conduct NSTs from Home", showcasing real-world data on over 2,000 remote NST sessions using Nuvo technology. The session highlighted the high at-home fetal monitoring success rates, demonstrating its potential to improve accessibility and patient outcomes. Special recognition goes to Nuvo's Dr. Amit Reches and Barak Laish for their dedication and contributions to this research.

Our esteemed partners at Philips attracted a large audience for their Learning Lunch session, "Obstetric Innovation that Transcends Care Settings." The discussion, led by Dr. Richie Broth, Dr. Sina Haeri, and Dr. Michael Ruma, provided insights into how remote pregnancy monitoring transforms prenatal care. The speakers covered advancements in remote fetal non-stress testing (NST), blood pressure monitoring, and glucose tracking, emphasizing how these technologies reshape obstetric care.

Obstetric Innovation & Scientific Forums

Nuvo was also thrilled to engage in the Scientific Forum on Obstetric Innovation, chaired by Dr. Adam Lewkowitz and Dr. Alisse Hauspurg. During the session, Dr. Richie Broth sparked an engaging discussion on remote fetal monitoring, addressing its benefits, challenges, and lessons learned from real-world applications. Attendees gained valuable insights into how remote NSTs can enhance clinical decision-making and improve patient adherence.

For those interested, Dr. Broth’s presentation slides are available for download HERE.

Dedicated Sessions on Remote Pregnancy Monitoring

Several additional sessions at SMFM 2025 explored various aspects of remote pregnancy monitoring (RPM):

• Dr. Christina Yarrington from the University of New Mexico led a session on "Remote Blood Pressure Monitoring (RPM)," emphasizing the importance of RPM in detecting and managing hypertensive disorders during pregnancy.
• A compelling poster presentation, "Perinatal Outcomes Following Implementation of a Remote Patient Monitoring Program for Hypertensive Disorders in Pregnancy," outlined the tangible benefits of RPM programs in improving maternal and fetal health outcomes.

Looking Ahead‍

SMFM 2025 reinforced the growing importance of remote pregnancy monitoring in modern maternal-fetal care. The enthusiasm and engagement from healthcare providers, researchers, and industry partners demonstrated the medical community's readiness to embrace innovative solutions that enhance patient care and accessibility. Nuvo remains committed to advancing remote pregnancy monitoring technology and looks forward to continuing our collaborations with healthcare providers and partners to improve maternal and fetal health outcomes worldwide. For more information about Nuvo's remote pregnancy monitoring solutions or to discuss potential partnerships, don't hesitate to get in touch with our team here.

The study, conducted at Sheba Beyond, Sheba Medical Center, Tel Hashomer virtual hospital, showcased the successful implementation of INVU™ alongside other digital health technologies in a comprehensive remote monitoring solution for gestational diabetes. 

Technology Integration Partners:

• NUVO (INVU™): Provided remote fetal monitoring capabilities enabling real-time professional interpretation of non-stress tests
• PulseNmore: Supplied remote ultrasound technology for measuring amniotic fluid maximal vertical pocket, enabling complete modified biophysical profile assessment from home
• Healthy.io: Delivered digital urinalysis technology for remote monitoring of protein levels and maternal health indicators
• Datos Health: Provided the digital platform for monitoring vital signs and glycemic control.

The integrated solution enabled:

• Remote non-stress testing with real-time professional interpretation
• Home-based fetal surveillance
• Continuous maternal health monitoring
• Digital glucose tracking and diabetes management
• Remote urinalysis and vital signs monitoring
• Comprehensive virtual care visits
• Integration with electronic health records

The study validated INVU's effectiveness in managing various high-risk pregnancy conditions, including:

• Gestational diabetes (both A1GD and A2GD)
• Pregnancies requiring antepartum fetal surveillance
• Cases needing regular non-stress tests
• Conditions requiring a modified biophysical profile
• High-risk pregnancies at or beyond 32 weeks gestation

The research team achieved a remarkable 97.4% success rate in completing remote maternal-fetal assessments, with visit durations reduced by nearly two-thirds compared to in-clinic appointments. Clinical outcomes were notably positive, with high patient satisfaction scores (6.6 out of 7) and improved adherence to glucose monitoring protocols during the hybrid care. The research demonstrated that INVU can be effectively integrated into a broader remote care ecosystem, providing comprehensive care for maternal hypertensive disorders, fetal growth monitoring, and high-risk pregnancy surveillance.

‍
This successful integration demonstrates INVU's pivotal role in the future of maternal-fetal medicine, particularly in managing complex pregnancies requiring regular monitoring and assessment. Healthcare providers looking to implement comprehensive remote care programs for maternal-fetal care can benefit from INVU's proven platform.

‍
Publication Details:  Authors: Michal Axelrod, Hila Lahav Ezra, Esther Galler, Omer Nir, Keren Ofir, Galia Barkai, Eyal Sivan, Shali Mazaki-Tovi, Abraham Tsur, "Hybrid Remote and In-Clinic Maternal-Fetal Surveillance for Women with Gestational Diabetes: A Prospective Pilot Study" Journal: International Journal of Gynecology & Obstetrics Publication.  

This was originally published in the International Journal of Gynecology & Obstetrics here.

‍

Objective

This study explores a hybrid approach to maternal-fetal care for gestational diabetes (GD), integrating virtual visits seamlessly with in-clinic assessments. We assessed the feasibility, time efficiency, patient satisfaction, and clinical outcomes to facilitate wider adoption of maternal-fetal telemedicine.

Methods

We conducted a 4-week prospective study involving 20 women with GD at ≥32 weeks of pregnancy, alternating between remote and in-clinic weekly visits. Remote assessments began with women self-measuring vital signs and using a digital urine dipstick. The remote encounter started with a midwife performing anamnesis and remotely connecting women to the fetal nonstress test. A physician concluded the meeting with remote sonographic assessment of amniotic fluid maximal vertical pocket that together with the nonstress test provided the modified biophysical assessment as well as a video encounter and ongoing glycemic control assessment. We assessed the feasibility of remote visits, compared visit durations, evaluated women's satisfaction using the Telehealth Usability Questionnaire, examined glucose documentation adherence during hybrid care compared with the following period until birth, and assessed GD-related clinical outcomes.

Results

Remote visits had a success rate of 97.4% (38 of 39), with significantly shorter durations compared with in-clinic visits (median 59.0 min vs. 159.0 min, P < 0.001). Women expressed high satisfaction (6.6 of 7), and adherence with recording fasting glucose values during the study period was significantly higher than the following period until birth (92.2% vs. 61.8%, P = 0.001). Notably, none required induction of labor for glycemic control imbalance, and there were no cases of macrosomia, shoulder dystocia, or neonatal hypoglycemia.

Conclusion

The hybrid approach to maternal-fetal care for GD demonstrated feasibility, safety, time efficiency, improved patient satisfaction, and enhanced glycemic control adherence.

‍

Nuvo™, an innovative healthcare company, is on a mission to revolutionize pregnancy care. The flagship product aims to empower pregnant women through remote monitoring– providing convenience and peace of mind to the moms and actionable insights for their care team.

Recently, Dr. Richard Broth, a renowned perinatologist and INVU by Nuvo™ prescribing physician, and Maggie Ockay, a Nuvo™ Customer Care Specialist,  sat down to dive deeper into their journey with Nuvo™, the challenges faced, and the impact that the groundbreaking device has on pregnancies worldwide.

About Nuvo™ and the INVU system

Nuvo’s mission is to transform pregnancy care by moving from the traditional, facility-based monitoring to remote monitoring with data-driven insights. The INVU system allows moms to monitor their pregnancy from the comfort of home, work, or even vacation. 

Here’s how it works:

1. Data Collection: The INVU sensor band captures vital data without a clinician physically present.
2. Cloud Processing: Data is analyzed in the cloud.
3. Digital Tools: Insights are provided to both moms and clinicians through a mobile application and provider dashboard.
4. Convenience and Peace of Mind: The system is prescription-initiated, enabling seamless integration into a care protocol for a patient, wherever the patient may be.

The INVU app allows moms to track their baby’s heart rate, hear a snippet of the heartbeat, and communicate with providers, creating a virtual in-office experience.

Dialogue with the Doctor

1. What are the exact checkups that can be performed with the belt?

Dr. Broth: The belt replicates an in-office non-stress test. It’s ideal for advanced maternal age, diabetes, high blood pressure, and other conditions. The data collected helps clinicians make actionable decisions remotely.

Guest Comment: “It’s reassuring to know that this device can help with high-risk pregnancies like mine!” said a participant in the forum.

2. Who decides when a remote checkup is done? Can patients decide?

Dr. Broth: Scheduling is a collaborative decision between the patient and physician. Most protocols suggest weekly monitoring, but schedules can be customized based on the patient’s needs.

Guest Comment: “I appreciate that it’s a team decision. It feels empowering to have input on my care schedule,” shared Lisa, an expectant mother.

3. What happens if I’m nervous about decreased fetal movement in the middle of the night?

Dr. Broth: With INVU, you can contact your on-call physician, who may initiate a remote session. This often saves a trip to the hospital and provides reassurance from the comfort of home.

Guest Comment: “This is exactly what I need. I’ve had too many sleepless nights wondering if I should go to the hospital,” commented Megan, a first-time mom.

4. Is there an option for self-monitoring?

Dr. Broth: No. The device is designed for clinical use under physician oversight to ensure medical safety. Patients cannot use it independently like a home doppler.

Guest Comment: “It’s good to know the boundaries. Safety first!” remarked a forum attendee.

A Patient’s Perspective

The forum included a testimonial from Alexis, a former patient. She highlighted the convenience of remote monitoring with INVU by Nuvo™, which allowed her to enjoy peace of mind without frequent clinic visits. “The device changed my perception of prenatal care. It’s a game-changer,” she said.

What’s next for Nuvo?

The team is focused on expanding accessibility of INVU by Nuvo™ for both moms and physicians. "Our vision is to integrate Nuvo into standard prenatal care worldwide," shared Ryan Kraudel, Chief Commercial Officer at Nuvo. "We’re also exploring AI-driven insights to enhance predictive capabilities."

The innovative device created by Nuvo™  is poised to transform the landscape of prenatal care, offering both convenience and clinical reliability. With glowing reviews from patients and healthcare professionals alike, it is clear this technology is filling a critical gap in pregnancy care.

Stay tuned for updates on Nuvo’s progress for creating a future of pregnancy care that looks brighter one patient at a time.

‍

Dr. Lawrence Platt is a renowned expert in obstetrics and gynecology, with a distinguished career spanning more than 50 years. He is recognized for his groundbreaking work in fetal assessment, maternal care, and medical imaging technologies. With an impressive track record of collaborating with startups and advancing innovative healthcare solutions, Dr. Platt has consistently pushed the boundaries of maternal-fetal medicine to improve patient outcomes.

Currently, Dr. Platt lends his expertise to Nuvo™, a trailblazing medical technology company revolutionizing prenatal care. Nuvo’s flagship product, INVU, has secured two FDA approvals offering leading-edge solutions for remote fetal monitoring. This innovation is transforming the way expectant mothers and healthcare providers approach prenatal assessments. By combining advanced technology with user-friendly design, INVU by Nuvo™ provides expectant mothers convenience and peace-of-mind, thereby enhancing  the quality of care, improving patient compliance, and making prenatal monitoring more accessible than ever before.

‍

Transforming Prenatal Care with Nuvo

Dr. Platt’s expertise in gynecology and obstetrics has often led him to collaborate with startups in maternal and fetal health, and his journey with Nuvo™ began during its early stages. He was drawn to Nuvo’s potential to improve the quality of care for pregnancies through innovative, patient-centered solutions.

Nuvo’s solution addresses significant challenges in fetal assessment by offering the option to have certain monitoring sessions done in the comfort and convenience  of the expectant mother’s home or office. . This reduces the logistical burden on expectant mothers, minimizing the need for frequent travel and easing time commitments. For mothers facing challenges such as distance, childcare, or transportation issues, Nuvo’s technology provides a vital lifeline. Additionally, it alleviates the strain on healthcare providers by reducing in-office resource demands, leading to cost savings for both patients and medical facilities.

Remote care advancements, particularly those accelerated during the COVID-19 pandemic, have underscored the value of innovations such as INVU by Nuvo™. Nuvo’s solution delivers results that are equivalent or superior to traditional in-clinic  monitoring methods. This breakthrough has the potential to establish new standards in prenatal care, enhancing compliance and enabling earlier detection of fetal distress. The system is especially beneficial for high-risk pregnancies, as it allows continuous monitoring from virtually anywhere with internet access and a direct link to your physician, supporting better perinatal outcomes.

With its ability to save time, reduce costs, and improve outcomes for mothers and babies alike, Nuvo has the potential to revolutionize prenatal care, offering a brighter and safer future for families worldwide.

‍

In a recent interview, Dr. Richard Broth, a renowned perinatologist at a private practice in the D.C., Maryland, and Virginia area, shared his thoughts on INVU by Nuvo™ , The Nuvo™ platform offers INVU, a wearable sensor band with cloud-based processing and software applications tailored for both mothers and physicians. With over two decades of experience in high-risk pregnancy care, Dr. Broth provides an authoritative perspective on how this technology is poised to transform the way pregnancies are monitored.

Meet Dr. Richard Broth

Dr. Broth's journey in medicine began at the University of Maryland, followed by a residency in New York, and a fellowship at Thomas Jefferson University in Philadelphia. Specializing in high-risk pregnancies, he has dedicated his career to ensuring the safety and well-being of both mothers and their babies.

When asked about his initial thoughts on Nuvo™, Dr. Broth revealed  - "I was blown away," he shared. "The concept of managing patients safely and competently from a distance was revolutionary, even before the pandemic made such solutions a necessity."

What Is Nuvo?

Nuvo’s core innovation lies in its convenience and exclusive technology—The INVU service is portable, self-applied band and mobile application that allows patients to monitor fetal health with the same or better quality than the standard tools used in doctors offices. Many pregnancies require frequent monitoring and Nuvo™ enables expectant mothers to perform tests in the comfort of their own homes. Dr. Broth explains, "It enables the same monitoring we do in the office, but now this cutting edge technology allows my patients to be at home, their workplace, or wherever they need to be. Imagine the evolution of a landline to a cell phone—the concept remains the same, but this technology and convenience changes everything."

Bridging Convenience and Safety

Dr. Broth’s enthusiasm for Nuvo™ is rooted in its ability to alleviate the burdens of frequent office visits. "For all patients and some with conditions like high blood pressure or diabetes, regular monitoring is essential. These patients often have to visit the office twice a week. With INVU, we can reduce these visits and the additional stress that comes along with them, providing higher levels of care while freeing up time for other patients who need in-office care."

The convenience extends to doctors as well. "Every doctor I’ve spoken to is intrigued. It’s FDA/CE -approved, which clears a significant hurdle. The key now is integrating it into office models and proving its value through real-world use," Dr. Broth noted.

Transforming Patient Experience

When asked about patient reactions, Dr. Broth shared insights from his experience as a pilot site for INVU. "Patients loved it. It was easy to use and allowed them to monitor their babies at times convenient for them, even outside typical office hours. I could communicate with them in real-time and provide immediate peace of mind that their baby is safe."

Addressing Concerns and Building Trust

For expectant mothers who might hesitate to adopt new technology, Dr. Broth has a simple message: “This isn’t a new concept. It’s the same test we perform in the office, now made mobile for your convenience. The FDA/CE approval assures that the results are consistent and reliable. It’s about maintaining the highest level of care that fits into your life and schedule, without compromising on safety.

The Road Ahead

Dr. Broth is optimistic about the future of INVU. “Over time, we’ll prove that this service not only saves babies but also saves money. Insurance companies will see its value, and more patients will benefit from this convenient and safe approach.”

As prenatal care continues to evolve, innovations like Nuvo™ are paving the way for a more patient-centered approach. With advocates like Dr. Broth leading the charge, the future of pregnancy monitoring looks brighter than ever.

‍